Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.
Dietz S, Sültmann H, Du Y, Reisinger E, Riediger AL, Volckmar AL, Stenzinger A, Schlesner M, Jäger D, Hohenfellner M, Duensing S, Grüllich C, Pahernik S. Dietz S, et al. Among authors: sultmann h. Oncotarget. 2017 May 23;8(43):74049-74057. doi: 10.18632/oncotarget.18200. eCollection 2017 Sep 26. Oncotarget. 2017. PMID: 29088767 Free PMC article.
[Urology in the concept of comprehensive cancer centers].
Hadaschik B, Pahernik S, Grüllich C, Sültmann H, Jäger D, von Kalle C, Duensing S, Hohenfellner M. Hadaschik B, et al. Among authors: sultmann h. Urologe A. 2013 Sep;52(9):1283-9. doi: 10.1007/s00120-013-3313-3. Urologe A. 2013. PMID: 23942742 Review. German.
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma.
Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C, Fiegl H, Müller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sültmann H, Altevogt P. Schirmer U, et al. Among authors: sultmann h. Oncotarget. 2014 Jan 30;5(2):462-72. doi: 10.18632/oncotarget.1552. Oncotarget. 2014. PMID: 24497324 Free PMC article.
Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity.
Hoefflin R, Lahrmann B, Warsow G, Hübschmann D, Spath C, Walter B, Chen X, Hofer L, Macher-Goeppinger S, Tolstov Y, Korzeniewski N, Duensing A, Grüllich C, Jäger D, Perner S, Schönberg G, Nyarangi-Dix J, Isaac S, Hatiboglu G, Teber D, Hadaschik B, Pahernik S, Roth W, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Grabe N, Duensing S. Hoefflin R, et al. Among authors: sultmann h. Nat Commun. 2016 Jun 13;7:ncomms11845. doi: 10.1038/ncomms11845. Nat Commun. 2016. PMID: 27291893 Free PMC article.
A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.
Castelo-Branco P, Leão R, Lipman T, Campbell B, Lee D, Price A, Zhang C, Heidari A, Stephens D, Boerno S, Coelho H, Gomes A, Domingos C, Apolonio JD, Schäfer G, Bristow RG, Schweiger MR, Hamilton R, Zlotta A, Figueiredo A, Klocker H, Sültmann H, Tabori U. Castelo-Branco P, et al. Among authors: sultmann h. Oncotarget. 2016 Sep 6;7(36):57726-57736. doi: 10.18632/oncotarget.10639. Oncotarget. 2016. PMID: 27437772 Free PMC article.
Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression.
Pickl JM, Tichy D, Kuryshev VY, Tolstov Y, Falkenstein M, Schüler J, Reidenbach D, Hotz-Wagenblatt A, Kristiansen G, Roth W, Hadaschik B, Hohenfellner M, Duensing S, Heckmann D, Sültmann H. Pickl JM, et al. Among authors: sultmann h. Oncotarget. 2016 Sep 13;7(37):59589-59603. doi: 10.18632/oncotarget.10729. Oncotarget. 2016. PMID: 27449098 Free PMC article.
220 results